Walleye Capital
MRNS

Walleye Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Walleye Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-185,424
Closed -$1.68M – 6178
2024
Q1 		$1.68M Sell
185,424
-67,077
-27% -$652K ﹤0.01% 2128
2023
Q4 		$2.74M Sell
252,501
-88,099
-26% -$660K 0.01% 1546
2023
Q3 		$2.74M Sell
340,600
-19,645
-5% -$163K 0.01% 1480
2023
Q2 		$3.91M Buy
360,245
+329,362
+1,066% +$2.82M 0.01% 886
2023
Q1 		$213K Sell
30,883
-809,874
-96% -$5.08M ﹤0.01% 2424
2022
Q4 		$3.35M Buy
840,757
+554,074
+193% +$2.72M 0.06% 380
2022
Q3 		$1.91M Buy
+286,683
New +$1.77M 0.04% 592
2022
Q1 		– Sell
-10,554
Closed -$125K – 2682
2021
Q4 		$125K Buy
+10,554
New +$122K ﹤0.01% 1614

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Walleye Capital's MRNS Position: Q2 2024 in Review

Walleye Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 185,424 shares — an estimated $1.68M sold.

Walleye Capital first reported a position in MRNS in Q4 2021 and held it in 8 quarters. The position peaked at $3.91M in Q2 2023. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Walleye Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Walleye Capital sold 185,424 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $1.68M.
  • Walleye Capital first reported a position in Marinus Pharmaceuticals, Inc in Q4 2021 and held it in 8 quarters.
  • Walleye Capital's Marinus Pharmaceuticals, Inc position peaked at $3.91M in Q2 2023.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.